

04-May-18 16:50

From-GOUVREAU GAGE DUBUC

MAY 18 2004 5149374382

T-065 P.01/07 F-710

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

Docket No.

13334.11

Applicant(s):

Serial No
10,088,405Filing Date
07/24/2002Examiner
UnknownGroup Art Unit
3762Invention: Local delivery of 17-Beta estradiol for preventing vascular intima hyperplasia and for improving
vascular endothelium function after vascular injury

I hereby certify that this Supplemental Information Disclosure Statement
(Identify type of correspondence)
is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. (703) 872-9302)
on May 18, 2004
(Date)

Julie Gauvreau Reg. No. 52,532

(Typed or Printed Name of Person Signing Certificate)

(Signature)

Note: Each paper must have its own certificate of mailing.

P1wREV01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

In re patent application of: Baskaran Chadrasekar et al.

MAY 18 2004

Atty. Docket No.: 12554.15

Serial No.: 10/088,405

Group Art Unit: 3762

Filed: 07/24/2002

Examiner: Unknown

Title: LOCAL DELIVERY OF 17-BETA ESTRADIOL FOR PREVENTING VASCULAR
INTIMA HYPERPLASIA AND FOR IMPROVING VASCULAR ENDOTHELIUM
FUNCTION AFTER VASCULAR INJURY

OFFICIAL

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97Commissioner for Patents
Alexandria VA 22313-1450

Sir:


Submitted herewith on a PTO-1449 form is a listing of the documents known to applicant in order to comply with applicant's duty of disclosure pursuant to 37 C.F.R. § 1.56. Copies of the listed documents are also being submitted herewith to comply with the provisions of 37 C.F.R. § 1.98, with copies of English translations of non-English language references or of the pertinent portions thereof, if such translations are readily available. If applicable, English copies of foreign search reports citing at least some of the documents herein listed on PTO-1449 are also enclosed.

The submission of any document which is not a statutory bar is not intended as an admission that such document constitutes prior art against the claims of the present application. Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

Statement of Relevancy

The listed documents are being submitted in compliance with 37 C.F.R. §1.97(e)(1), i.e. within three (3) months from the date of an office action or of a search report issued in a foreign counterpart application citing each of the documents contained in the present statement. The undersigned Agent of Record hereby certifies that the enclosed references are hereby submitted within three months from the issuance of the office action or foreign search report.

Respectfully submitted,


Julie Gauvreau
Registration No. 52,532

Date May 18, 2004

GOUDREAU GAGE DUBUC
Stock Exchange Tower
Suite 3400, P.O. Box 242
800 Place-Victoria
Montreal, Quebec, Canada
H4Z 1E9
Tel.: (514) 397-4374

Form PTO-1449 (Rev 7-80)	U.S. Department of Commerce Patent & Trademark Office	ATTY.DOCKET NO 12554.15	SERIAL NO. 10/088,405
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Baskaran Chadrasekar
		FILING DATE 07/24/2002	GROUP 3762

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

		<p>Akkad, A et al., "The effect of estrogen on intimal hyperplasia in cultures human ovarian veins"; Human Reproduction 13(6): 1449-1454, 1998 (Abstract).</p> <p>Bruck et al., "Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits »; Arteriosclerosis, Trombosis, and Vascular Biology, 17(10): 2192-2199, 1997 (Abstract).</p>
		<p>Yaki Kunio, "Anti-Arteriosclerotic Agent", Patent Abstracts of Japan, Publication No. 08165242, 1994.</p>

Examiner	Date considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	